Author
@Pharmdca Pharmdca
grade Cx.com/Pharmdca ↗
Long-only dip-buying biotech-and-megacap-tech bull who discloses every entry
Posts real-time, ticker-specific add/trim/buy-the-dip disclo
trader score
-3.41
hit rate
10%
mean α
-2.14%
signals 14d
156
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 10% hit rate, -2.14% mean alpha, trader score -3.41. Their last-14d mentions, direction-adjusted, have moved -2.2% since posting (mean over 120 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | MRNA | @Pharmdca | +0.05 | Discloses an existing TNGX long while watching TNGX and MRNA into ESMO. | -8.2% | tweet ↗ |
| 2026-10-16 | TNGX | @Pharmdca | +0.60 | Discloses an existing TNGX long while watching TNGX and MRNA into ESMO. | +5.9% | tweet ↗ |
| 2026-10-16 | META | @Pharmdca | +0.15 | Flags Meta earnings for the following week. | -9.4% | tweet ↗ |
| 2026-10-16 | OIL | @Pharmdca | +0.45 | Notes oil near yearly highs and high local fuel prices despite bearish rhetoric. | · | tweet ↗ |
| 2026-10-16 | MRNA | @Pharmdca | -0.35 | Warns priced-in optimism leaves MRNA vulnerable if Phase 3 efficacy disappoints. | -8.2% | tweet ↗ |
| 2026-10-15 | TSLA | @Pharmdca | +0.35 | Expresses strong enthusiasm for the Roadster's claimed acceleration. | +2.7% | tweet ↗ |
| 2026-10-15 | TSLA | @Pharmdca | +0.20 | Briefly expresses enthusiasm for Tesla's Roadster. | +2.7% | tweet ↗ |
| 2026-10-15 | SLDB | @Pharmdca | +0.85 | Accumulating SLDB on the pullback for a favorable risk-reward reversal. — Discloses active accumulation with valuation, pipeline and catalyst thesis. | · | tweet ↗ |
| 2026-10-15 | XBI | @Pharmdca | +0.90 | Buy the XBI dip while biotech sentiment is deeply negative. — Explicitly calls for buying the biotech dip based on fear-driven opportunity. | -0.2% | tweet ↗ |
| 2026-10-15 | SPY | @Pharmdca | +0.25 | Reports broad index reversals from morning declines into positive territory. | -1.5% | tweet ↗ |
| 2026-10-15 | XBI | @Pharmdca | +0.25 | Reports broad index reversals from morning declines into positive territory. | -0.2% | tweet ↗ |
| 2026-10-15 | PCVX | @Pharmdca | +0.45 | Watchlist identifies potential support and bounce setups; PCVX is called a buy opportunity. | · | tweet ↗ |
| 2026-10-15 | AAOI | @Pharmdca | +0.20 | Watchlist identifies potential support and bounce setups; PCVX is called a buy opportunity. | -19.4% | tweet ↗ |
| 2026-10-15 | NBIS | @Pharmdca | +0.20 | Watchlist identifies potential support and bounce setups; PCVX is called a buy opportunity. | -15.7% | tweet ↗ |
| 2026-10-15 | CRWV | @Pharmdca | +0.20 | Watchlist identifies potential support and bounce setups; PCVX is called a buy opportunity. | -22.2% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.